Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

Corporates don't want Copilot Software King of the World, Microsoft is finding out the hard way that even a decades-long grip ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Accord Healthcare’s Henlius-partnered Hetronifly ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

The AMG Montrusco Bolton Large Cap Growth Fund returned -5.88% during the first quarter, compared to the -8.47% return for ...